ATRC-301 / Atreca - LARVOL DELTA

Discovery and pre-clinical development of a novel and differentiated EphA2-targeted antibody in multiple bispecific formats (SITC 2022) - "Results An anti-EphA2 antibody was identified from plasmablasts of a patient with lung cancer after treatment with nivolumab...A weak 4-1BB agonist paired with tumor targeting drove cross-linking and activation at the tumor and dose-dependently inhibited tumor growth while avoiding the alanine transaminase increases observed with a urelumab surrogate...Separately, an antibody–drug conjugate version, ATRC-301, is entering IND-enabling studies and is described elsewhere...Optimized leads with high potency and developability exhibit anti-tumor activity in multiple formats, including a 4-1BB bispecific. These data demonstrate the power of our antibody discovery platform to uncover unique antibodies and their epitopes."

Preclinical • Lung Cancer • Oncology • Solid Tumor • FN1

Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update (GlobeNewswire) - "An non-human primate (NHP) toxicity study to evaluate ATRC-301, an antibody drug conjugate (ADC) candidate in our anti-EphA2 program, revealed safety signals, including bleeding, and as a result, Atreca is discontinuing the development of ATRC-301."

Discontinued • Preclinical • Oncology

Atreca Announces Expansion of Preclinical Pipeline (GlobeNewswire) - "Atreca...announced a licensing agreement with Zymeworks...to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates (ADCs) and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the Company’s next clinical candidate....'We are targeting one additional Investigational New Drug (IND) application per year beginning with ATRC-301 in the second half of 2023'....Atreca is advancing multiple additional lead-stage programs in oncology, including ADC leads APN-497444 and APN–959038, CD3-engager lead APN-346958, and IL-15 superagonist (SA) conjugate lead APN-541885."

IND • Licensing / partnership • Pipeline update • Oncology